Mr. Weiss has been our Chief Executive Officer since October 2014 and has served on our board of directors since October 2014. Prior to that, he served as our Co-Chief Executive Officer from November 2013 until October 2014. Prior to serving as our Co-Chief Executive Officer, he served as our Executive Vice President of Commercial Operations commencing in September 2006. Mr. Weiss has approximately 15 years of experience in healthcare corporate development, strategic planning and corporate finance. Prior to his service with us, Mr. Weiss served as the Head of Life Sciences Strategic consulting with PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2006. He is a certified public accountant in Israel, and has a BSc in Biology, a B.A. in accounting and has completed MSc studies in neuro-biochemistry, each from Tel Aviv University in Tel Aviv, Israel.
Dr. Nadav Navon has been with us since March 2006 and has served as our Executive Vice President of Research & Development and Operations since March 2015. Before that he served as our Vice President of Research & Development and Operations since May 2013. Prior to his service with us, Dr. Navon headed the analytical and quality assurance operations at Sharon Laboratories Ltd., a chemical company that develops and manufactures raw materials for the pharmaceutical, cosmetic and food industries, from 2001 to 2006. Prior to that, Dr. Navon led a number of research and development projects in the Negev’s Nuclear Research Center. Dr. Navon has a Ph.D. in inorganic and analytical chemistry, and an MBA and a BSc in chemistry, each from Ben-Gurion University in Beer-Sheva, Israel.
Mr. Nir Sassi has been our Chief Financial Officer since August 2016. Prior to serving as our Chief Financial Officer, he served as our VP Finance commencing in March 2010. Prior to his service with us, Mr. Sassi served as a Senior Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor’s degree in economics and accounting from Ben Gurion University in Beer Sheva, Israel.
Dr. Anna Hotovely-Salomon is serving as our Director Clinical Affairs. Prior to joining Intec Pharma, she held a position of Senior Global Clinical Project Manager at Quintiles, managed large cross-functional project teams to support Phase II/III studies. Anna also led Phases I, II and III clinical trials as Global Operational Manager in TEVA Pharmaceutical Company and prior to that she served as R&D Project Manager of Tissue Regeneration. Anna has over 18 years of experience in Biotechnology and gained considerable experience in managing Clinical Trials. Anna holds a PhD degree in Biomedical Polymers, Applied Chemistry from the Hebrew University, Jerusalem, Israel.